Runcaciguat

Runcaciguat
Legal status
Legal status
  • Investigational
Identifiers
  • (3S)-3-[4-Chloro-3-[[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino]phenyl]-3-cyclopropylpropanoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC23H22Cl2F3NO3
Molar mass488.33 g·mol−1
3D model (JSmol)
  • C[C@H]([C@@H](C1=CC=C(C=C1)Cl)C(=O)NC2=C(C=CC(=C2)[C@@H](CC(=O)O)C3CC3)Cl)C(F)(F)F
  • InChI=1S/C23H22Cl2F3NO3/c1-12(23(26,27)28)21(14-4-7-16(24)8-5-14)22(32)29-19-10-15(6-9-18(19)25)17(11-20(30)31)13-2-3-13/h4-10,12-13,17,21H,2-3,11H2,1H3,(H,29,32)(H,30,31)/t12-,17+,21+/m1/s1
  • Key:NCRMKIWHFXSBGZ-CNBXIYLPSA-N

Runcaciguat is a soluble guanylate cyclase activator developed by Bayer for non-proliferative diabetic retinopathy and chronic kidney disease.[1][2][3]

References

  1. ^ Bénardeau, Agnès; Kahnert, Antje; Schomber, Tibor; Meyer, Jutta; Pavkovic, Mira; Kretschmer, Axel; Lawrenz, Bettina; Hartmann, Elke; Mathar, Ilka; Hueser, Joerg; Kraehling, Jan R.; Eitner, Frank; Hahn, Michael G.; Stasch, Johannes-Peter; Sandner, Peter (December 2021). "Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease". Naunyn-Schmiedeberg's Archives of Pharmacology. 394 (12): 2363–2379. doi:10.1007/s00210-021-02149-4. PMC 8592982. PMID 34550407.
  2. ^ Hahn, Michael G.; Lampe, Thomas; El Sheikh, Sherif; Griebenow, Nils; Woltering, Elisabeth; Schlemmer, Karl-Heinz; Dietz, Lisa; Gerisch, Michael; Wunder, Frank; Becker-Pelster, Eva-Maria; Mondritzki, Thomas; Tinel, Hanna; Knorr, Andreas; Kern, Armin; Lang, Dieter; Hueser, Joerg; Schomber, Tibor; Benardeau, Agnes; Eitner, Frank; Truebel, Hubert; Mittendorf, Joachim; Kumar, Vijay; van den Akker, Focco; Schaefer, Martina; Geiss, Volker; Sandner, Peter; Stasch, Johannes-Peter (13 May 2021). "Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042)". Journal of Medicinal Chemistry. 64 (9): 5323–5344. doi:10.1021/acs.jmedchem.0c02154. PMID 33872507. S2CID 233311492.
  3. ^ Nelissen, Ellis; Possemis, Nina; Van Goethem, Nick P.; Schepers, Melissa; Mulder-Jongen, Danielle A. J.; Dietz, Lisa; Janssen, Wiebke; Gerisch, Michael; Hüser, Jörg; Sandner, Peter; Vanmierlo, Tim; Prickaerts, Jos (4 March 2022). "The sGC activator BAY-747 and activator runcaciguat can enhance memory in vivo via differential hippocampal plasticity mechanisms". Scientific Reports. 12 (1): 3589. Bibcode:2022NatSR..12.3589N. doi:10.1038/s41598-022-07391-1. ISSN 2045-2322. PMC 8897390. PMID 35246566.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.